ANI Pharmaceuticals (ANIP) Stock Forecast, Price & News

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

Is ANI Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANI Pharmaceuticals stock.
View analyst ratings for ANI Pharmaceuticals or view top-rated stocks.

When is ANI Pharmaceuticals' next earnings date?

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 5th 2022.
View our earnings forecast for ANI Pharmaceuticals.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) posted its quarterly earnings results on Tuesday, May, 10th. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.21. ANI Pharmaceuticals had a positive trailing twelve-month return on equity of 6.66% and a negative net margin of 27.78%. During the same quarter in the prior year, the firm posted $0.92 EPS.
View ANI Pharmaceuticals' earnings history.

What guidance has ANI Pharmaceuticals issued on next quarter's earnings?

ANI Pharmaceuticals issued an update on its FY 2022 earnings guidance on Tuesday, May, 24th. The company provided earnings per share guidance of $1.34-$1.62 for the period, compared to the consensus EPS estimate of $1.15. The company issued revenue guidance of $295.00 million-$315.00 million, compared to the consensus revenue estimate of $292.77 million.

What price target have analysts set for ANIP?

3 equities research analysts have issued twelve-month price objectives for ANI Pharmaceuticals' shares. Their forecasts range from $47.00 to $70.00. On average, they expect ANI Pharmaceuticals' share price to reach $58.50 in the next twelve months. This suggests a possible upside of 88.6% from the stock's current price.
View analysts' price targets for ANI Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the following people:

• Mr. Nikhil Lalwani, Pres, CEO & Director (Age 44, Pay $2.17M)
• Mr. Stephen P. Carey, CFO, Sr. VP of Fin. & Corp. Sec. (Age 51, Pay $1.11M)
• Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 59, Pay $709.02k)
• Mr. Christopher K. Mutz, Head of Rare Disease (Age 50, Pay $643.58k)
• Mr. Ori Gutwerg, Sr. VP of Generics (Age 48, Pay $710.74k)
• Mr. Muthusamy Shanmugam MS R.Ph., Head of R&D, COO of Novitium Operations & Director (Age 54)
• Mr. Chad Gassert, Sr. VP of Corp. Devel. & Strategy (Age 46)
• Ms. Elizabeth Powell J.D., Chief Compliance Officer & Head of Legal of Rare Disease
• Dr. Mary Pao M.D., Ph.D., Chief Medical Officer of Rare Disease

What is Arthur Przbyl's approval rating as ANI Pharmaceuticals' CEO?

1 employees have rated ANI Pharmaceuticals CEO Arthur Przbyl on Glassdoor.com. Arthur Przbyl has an approval rating of 100% among ANI Pharmaceuticals' employees. This puts Arthur Przbyl in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of ANI Pharmaceuticals' key competitors?

Some companies that are related to ANI Pharmaceuticals include Schrödinger (SDGR), Amphastar Pharmaceuticals (AMPH), Sage Therapeutics (SAGE), Emergent BioSolutions (EBS), Turning Point Therapeutics (TPTX), Ironwood Pharmaceuticals (IRWD), Global Blood Therapeutics (GBT), Aurinia Pharmaceuticals (AUPH), ChemoCentryx (CCXI), HUTCHMED (HCM), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Supernus Pharmaceuticals (SUPN), Travere Therapeutics (TVTX) and Xenon Pharmaceuticals (XENE).
View all of ANIP's competitors.

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (gild), Micron Technology (MU), AbbVie (ABBV), Teva Pharmaceutical Industries (TEVA), Alibaba Group (BABA), Broadcom (AVGO), Cisco Systems (CSCO), Exelixis (EXEL) and Intel (INTC).

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.73%), Vanguard Group Inc. (4.49%), William Blair Investment Management LLC (3.31%), Dimensional Fund Advisors LP (2.64%), State Street Corp (2.48%) and Thompson Siegel & Walmsley LLC (2.46%). Company insiders that own ANI Pharmaceuticals stock include Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh and Thomas Haughey.
View institutional ownership trends for ANI Pharmaceuticals.

Which major investors are selling ANI Pharmaceuticals stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including Parkman Healthcare Partners LLC, 1492 Capital Management LLC, Goldman Sachs Group Inc., Bank of New York Mellon Corp, State Street Corp, Renaissance Technologies LLC, Russell Investments Group Ltd., and Victory Capital Management Inc..
View insider buying and selling activity for ANI Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying ANI Pharmaceuticals stock?

ANIP stock was bought by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, BlackRock Inc., Thompson Siegel & Walmsley LLC, William Blair Investment Management LLC, Dimensional Fund Advisors LP, Global Alpha Capital Management Ltd., and Vanguard Group Inc.. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include Jeanne Thoma, Muthusamy Shanmugam, Nikhil Lalwani, Patrick D Walsh, and Thomas Haughey.
View insider buying and selling activity for ANI Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $31.02.

How much money does ANI Pharmaceuticals make?

ANI Pharmaceuticals has a market capitalization of $535.78 million and generates $216.14 million in revenue each year. The specialty pharmaceutical company earns $-42.60 million in net income (profit) each year or ($4.530010) on an earnings per share basis.

How many employees does ANI Pharmaceuticals have?

ANI Pharmaceuticals employs 601 workers across the globe.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at (218) 634-3500, via email at [email protected], or via fax at 218-634-3540.